உறுதியானது ஓனிக்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உறுதியானது ஓனிக்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உறுதியானது ஓனிக்ஸ் Today - Breaking & Trending Today

Medtronic Launches Newest-Generation Drug Coated Balloon Catheter in Europe for Treatment of Coronary Artery Disease

Medtronic Launches Newest-Generation Drug Coated Balloon Catheter in Europe for Treatment of Coronary Artery Disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Jason Weidman , Azeem Latib , Lauren Mueller , Ryan Weispfenning , Exchange Commission , Montefiore Medical Center , Medtronic Prevail , Treat Complex Lesions , Superior Deliverability , Rapid Absorption , Renal Denervation , Cardiovascular Portfolio , Medtronic Resolute Onyx , Resolute Onyx , Diagnostic Angiography Catheter , Guide Extension , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஜேசன் வீட்மேன் , லாரன் முல்லர் , பரிமாற்றம் தரகு , மான்டிஃபியோர் மருத்துவ மையம் , இருதய போர்ட்‌ஃபோலீயோ , மெதிடிறோனிக் உறுதியானது ஓனிக்ஸ் ,

FDA Permits 28-Day DAPT in Xience-Treated Patients at High Bleeding Risk

FDA Permits 28-Day DAPT in Xience-Treated Patients at High Bleeding Risk
tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.

Drug Administration , Resolute Onyx , உறுதியானது ஓனிக்ஸ் ,

Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.
The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx, a leading drug-eluting stent (DES). The primary endpoint of the study is target lesion failure at one year. Secondary endpoints include measures of the implants ability to accommodate vessel growth from disease progression and restore artery pulsatility in an imaging subset, as well as other major c ....

United States , Coll Cardiol , Michelle Mcadam , Kostenloser Wertpapierhandel , Shigeru Saito , Stefan Verheye , Austrian Wiktor Stent Study Group , Antwerp Cardiovascular Centre , Elixir Medical Corporation , Catheterization Laboratory At Shonan Kamakura , Chronic Communications Inc , Elixir Medical , Dynamx Coronary Bioadaptor System , Dynamx Bioadaptor , Resolute Onyx , Catheterization Laboratory , Shonan Kamakura General Hospital , Antwerp Cardiovascular , Medical Corporation , Varying Outcomes With , Absorb Bioresorbable Vascular Scaffold During , Year Follow Up , Systematic Meta Analysis , Individual Patient Data Pooled , Randomized Controlled Trial , Paclitaxel Eluting Stents ,

Primary PCI Underused but Just as Effective in Cancer Patients With STEMI

February 04, 2021
Patients with cancer, including hematologic, breast, and lung cancer, who present with STEMI fare just as well with primary PCI as those without cancer, according to the results of a new study.
While primary PCI is underutilized in this high-risk group, with just half of lung cancer patients, for example, taken to the cath lab for revascularization, researchers found there was no significant difference in the risk of in-hospital major adverse cardiovascular and cerebrovascular events or all-cause mortality based on whether STEMI patients had cancer.
“Overall, these findings should provide some reassurance or evidence for operators who might be more cautious and potentially worried about causing harm in this high-risk group,” lead investigator Mohamed O. Mohamed, MBBCh (Keele University/Royal Stoke University Hospital, Stoke-on-Trent, England), told TCTMD. ....

United States , Mohamedo Mohamed , Pzf Celonova Biosciences , Cezar Iliescu , Harriette Van Spall , National Inpatient Sample , Md Mcmaster University , Mbbch Keele University Royal Stoke Hospital , Society For Cardiovascular Angiography , Dphil Keele University Royal Stoke Hospital , Royal Stoke University Hospital , Cancer Center , Cardiovascular Angiography , European Heart Journal , Acute Cardiovascular Care , National Inpatient , Resolute Onyx , Cobra Pzf , Celonova Biosciences , Mcmaster University , ஒன்றுபட்டது மாநிலங்களில் , ஹாரியட் வேன் ஸ்ப்பல்ல் , தேசிய உள்நோயாளி மாதிரி , ம்ட் மக்மாஸ்டர் பல்கலைக்கழகம் , ம்பிபிச் கீல் பல்கலைக்கழகம் அரச ஸ்டோக் மருத்துவமனை , சமூகம் க்கு இருதய ஆஞ்சியோகிராபி ,